AstraZeneca Chips Away At Seroquel Case

Law360, New York (July 30, 2007, 12:00 AM EDT) -- In the multidistrict litigation alleging its antipsychotic Seroquel causes diabetics, AstraZeneca wants the court to grant it partial judgment based on federal preemption, and to toss another 32 plaintiffs from the case for allegedly failing to submit medical records.

In a memorandum filed Tuesday, the drug company said the plaintiffs' state law failure-to-warn claims alleging inadequate labeling were barred because they conflicted with federal law.

“Indeed, they involve a direct assault on the FDA’s authoritative federal determinations concerning the appropriate diabetes-related warnings that must accompany Seroquel,”...
To view the full article, register now.